Breast density is one of the most common reasons for failure of mammography to detect cancer and presents unique challenges for breast cancer patients and providers. Despite being a well-established independent risk factor for breast cancer(1), 95% of women do not know their breast density.
Capitalizing on the European Union Horizon 2020 research and innovation program, Dune Medical has completed the first phase in the development of its percutaneous soft tissue biopsy device.
It’s been one year since our relocation to Atlanta in August 2017. We have been incredibly busy these past 12 months, and here are some of the highlights!
With sustainability in mind, Dune designed a reposable version of MarginProbe. The new reposable MarginProbe has a reusable cable and handle and a single-use attachable probe. The new probe has the potential to reduce waste burden of MarginProbe up to 50%.
Healthcare Reporter Lucette Lagnado profiles MarginProbe® in The Wall Street Journal featuring Dr. Freya Schnabel, Dr. Alice Police, Dr. Vincent Reid, Dune Medical CEO Lori Chmura and more.